Drug guidance
Tyrosine kinase inhibitors for treating MET mutation-positive metastatic non-small-cell lung cancer
Condition
Cancer
Respiratory
31 August 2022
Published on 31 Aug 2022
Last Updated on 31 Aug 2022
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Tepotinib 225 mg tablet
for treating metastatic mesenchymal epithelial transition exon 14 skipping (METex14sk) mutation-positive non-small-cell lung cancer (NSCLC) in line with specific clinical criteria.
Funding status
Tepotinib 225 mg tablet is recommended for inclusion on the MOH Cancer Drug List (CDL; MAF with MediShield Life monthly claim limit of $1,600) for the abovementioned indication from 1 September 2022.
CDL listing does not apply to any formulations or strengths of capmatinib for treating metastatic METex14sk mutation-positive NSCLC.
Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.
Tyrosine kinase inhibitors for MET mutation-positive metastatic NSCLC (31 Aug 22) [PDF, 133 KB]
Treatments for MET exon 14 skipping mutated metastatic NSCLC PES (31 Aug 22) [PDF, 83 KB]